Biotie is rapidly approaching the key nalmefene Phase III data readout around the year end. Under its licensing deal with Lundbeck, it could receive up…
Biotie retains global (ex-Asia) development and commercialisation rights to BTT-1023, its fully human VAP-1 monoclonal antibody, following a decision by…
2010 should be an interesting year for Biotie. Recent positive Phase I rheumatoid arthritis data from VAP-1 antibody BTT-1023, coupled with results of…